GoodLife Health prescribes branded GLP-1, never compounded, because branded medicines are reviewed by the FDA for safety, effectiveness and quality before they are sold. Compounded versions are not. A clinical protocol also depends on knowing exactly what a patient takes. Branded medication gives that certainty.

The alternative often arrives in a box with a vial from a pharmacy you had never heard of until last month, a printed label, a syringe and a dosing chart. The price was right. Then a quieter question arrives with it. What exactly is in this vial and who checked it? We want every member to be able to answer that question without hesitation, every week they take a dose.

If you have used compounded GLP-1, you did nothing wrong. Compounding was permitted while these medicines were in shortage. Since then, the ground has shifted. This piece covers what branded approval means, what the FDA has said about compounded GLP-1 as of November 2026, what branded GLP-1 costs now and how it feels to be the person taking the medicine. Our clinicians prescribe branded medication only, so we have a stake in this question. Every claim below carries its date and its source. We also tell you what we do not claim.

Key Takeaways
  • Branded GLP-1 medicines are reviewed by the FDA for safety, effectiveness and quality before they are sold. Compounded versions are not.
  • The FDA says compounded drugs should be used only when an approved drug cannot meet a patient's medical needs.
  • As of May 31, 2026, the FDA had received 990 adverse-event reports for compounded semaglutide and more than 730 for compounded tirzepatide. It considers these likely to be underreported.
  • Branded prices are published. As of November 2026, the Wegovy pill starts at $149 a month and Wegovy pens are $349 a month after a new patient's first two fills.
  • GoodLife Health prescribes branded, FDA-approved GLP-1 only, when it is indicated, at your pharmacy's own price and with nothing taken by us.

What does "branded" actually mean?

A branded GLP-1 is a medicine such as Wegovy, Zepbound, Mounjaro or Ozempic that the FDA approved after reviewing the manufacturer's evidence on safety, effectiveness and quality. Approval covers the molecule and also how it is made, how it is tested and how it is labeled. Every pen or tablet is meant to deliver the same dose of the same active ingredient as the ones studied.

The large clinical trials that taught medicine what these drugs can do were run on the branded products. The STEP 1 trial tested semaglutide 2.4 mg in adults over 68 weeks (NEJM, 2021). The SURMOUNT-1 trial tested tirzepatide in adults over 72 weeks (NEJM, 2022). A trial result is not a promise to any one person. What they do establish is how a known medicine at a known dose tends to behave.

What the evidence was built on
68 weeks
length of the STEP 1 trial of semaglutide 2.4 mg
72 weeks
length of the SURMOUNT-1 trial of tirzepatide
990
FDA adverse-event reports for compounded semaglutide, as of May 31, 2026
730+
FDA adverse-event reports for compounded tirzepatide, as of May 31, 2026

What does the FDA say about compounded GLP-1?

The FDA's own page on unapproved GLP-1 drugs used for weight loss, current as of October 1, 2026, makes several points directly (FDA).

  • Compounded GLP-1 is not FDA-approved. The agency does not review compounded drugs for safety, effectiveness or quality before they are marketed.
  • Compounding is meant for a narrow case. Compounded drugs should be used only when an approved drug cannot meet a patient's medical needs.
  • Some products are not the same ingredient. The FDA notes that some compounded semaglutide has been made with salt forms, which are different active ingredients than those in the approved drugs.
  • Adverse events are being reported. As of May 31, 2026, the agency had received 990 reports for compounded semaglutide and more than 730 for compounded tirzepatide. It considers these likely to be underreported. It cannot always determine whether a drug caused a given event.
  • Dosing errors have been reported. The FDA has received reports of dosing errors with compounded injectable semaglutide, some of them requiring hospitalization.
What the FDA says

Compounded drugs are not FDA-approved. The agency does not review them for safety, effectiveness or quality before they are marketed.

What changed in 2025 and 2026?

Compounding of these medicines grew while branded supply was short. The FDA declared the tirzepatide shortage resolved in December 2024 and the semaglutide shortage resolved on February 21, 2025 (FDA). With the shortages over, the reason for mass compounding went with them.

Enforcement has continued since. On October 9, 2026, the FDA published Import Alert 66-80. It allows GLP-1 active ingredients arriving at the border to be detained without examination unless the firm is on the agency's Green List. It records 48 GLP-1 ingredient sites inspected or reviewed (FDA). On October 30, 2026, the FDA issued a warning letter finding that marketing which implied compounded semaglutide and tirzepatide were FDA-approved was false or misleading.

Researchers at Eli Lilly, which makes Zepbound and Mounjaro, published a preprint in March 2026 describing a previously unidentified impurity in compounded tirzepatide products combined with vitamin B12. They report that its clinical effects are unknown (medRxiv). Lilly has a commercial interest in this question. The work is theirs and we cite it as their finding.

GoodLife Health. Medicine that builds on itself, $299 a month: 90-day labs, your clinician, branded GLP-1s, one platform. See if you qualify.GoodLife Health. $299 a month. Everything talks to everything: quarterly labs read by your clinician, branded GLP-1s prescribed from them, every result and dose tracked on one platform. See if you qualify.

How much does branded GLP-1 cost now?

The strongest argument for compounded GLP-1 was always price. Branded prices are now published by the manufacturers themselves. As of November 2026, Novo Nordisk lists these self-pay prices through NovoCare:

Branded GLP-1 self-pay prices

Manufacturers' own pages, as of November 2026

MedicineSelf-pay price
Wegovy pill 1.5 mg$149 a month
Wegovy pill 4 mg$199 a month
Wegovy pill 9 mg and 25 mg$299 a month
Wegovy pens, new patient's first two fills$199 a month, through December 31, 2026
Wegovy pens, after that$349 a month at every dose
Foundayo (orforglipron) through LillyDirectFrom $149 a month at the lowest dose

Lilly's Foundayo, approved on April 1, 2026, is a GLP-1 pill that starts at $149 a month at its lowest dose through LillyDirect (Lilly). Prices change, so we always print the date beside them.

How does it feel to be the person taking it?

The facts matter. So does what it is like to live with the decision every week.

You don't accept "close enough" anywhere else in your life. You read the label on what you eat. A weekly medicine that changes how your body handles food deserves at least the same scrutiny. With a branded pen or tablet, you know the manufacturer, the dose and the evidence behind it. If something feels wrong, your clinician knows exactly what you took.

There is a practical side as well. A clinical protocol works by reading your response to a known medicine at a known dose, then adjusting. When the product itself can vary, it becomes harder to tell whether a change in how you feel comes from your body, your dose or the vial. Branded medication removes that uncertainty from the reading.

You don't accept "close enough" anywhere else in your life.

Why branded only

What should you ask about any GLP-1 you are offered?

Whoever prescribes it, these questions tell you what you are taking.

  1. Is it FDA-approved? Ask for the brand name. Wegovy, Zepbound, Mounjaro and Ozempic are approved medicines. A compounded product has no FDA approval of its own.
  2. Who makes it? A branded pen or tablet carries the manufacturer's name. A compounded vial carries the name of the pharmacy that mixed it.
  3. What is the dose and how is it measured? A branded pen delivers a set dose. A vial and syringe leave the measuring to you.
  4. Who do I contact if something feels wrong? Ask whether it is a clinician who knows your history and your labs.

If every answer is clear, you know what you are taking. That certainty is the reason our clinicians prescribe branded medication only.

What do we not claim?

We do not say that compounded GLP-1 is dangerous in itself. Pharmacies also differ. We do not claim compounded products are diluted or cause more side effects, because we have no verified source for that. Every prescriber's license carries responsibility for what they prescribe, ours included. Our position is a choice about evidence and certainty. We prescribe branded, FDA-approved GLP-1 only, never compounded, at any price.

What if you take compounded GLP-1 today?

Talk to a clinician before you change anything. Tell us what you take, the dose, when you last took it and who prescribes it. Upload any labs you have. Bring the pharmacy's label or a clear photo of it as well, so your clinician can see the product, the strength and the dosing instructions you were given. That record lets your clinician compare what you take now with the branded options. Your baseline panel is drawn within days of joining. Your clinician reads it against your history and your current dose in a video visit, then decides with you what comes next. We prescribe branded, FDA-approved medication only when your labs and history say it is right.

The membership is $299 a month at every dose. Your medication is billed by your own pharmacy at its own price. GoodLife Health takes nothing on it, so no prescription we write earns us more than another. Year one is $3,588. Your first two months are covered by a $598 hold, charged only once a clinician accepts you into care. If a clinician cannot accept you, the hold is released and you are never charged. Once you are accepted, the first two months are non-refundable. Additional labs beyond the quarterly panel are billed separately by the lab.

Our medical weight loss membership page explains how the care works for GLP-1 in particular. For the cost comparison in depth, read compounded vs branded GLP-1.

Who is this not for?

Branded medication is a deliberate choice. It is rarely the lowest price on the market. If price is the deciding factor, another service will suit you better. We will not prescribe compounded GLP-1 to compete. The membership is also not designed for anyone seeking a prescription without labs or a guaranteed result. It sits alongside your health insurance rather than replacing it. Membership is open to adults living in the United States.

Frequently Asked Questions

Why does GoodLife Health prescribe branded GLP-1, never compounded?

Branded medicines are reviewed by the FDA for safety, effectiveness and quality before they are sold. Compounded versions are not. A protocol also depends on knowing exactly what you take. Branded medication gives that certainty.

Is compounded semaglutide the same medicine as Wegovy?

Not always. The FDA notes that some compounded semaglutide has been made with salt forms, which are different active ingredients than those in the approved drugs.

Is compounded GLP-1 still allowed?

The FDA says compounded drugs should be used only when an approved drug cannot meet a patient's medical needs. The shortages that drove mass compounding were declared resolved in December 2024 for tirzepatide and in February 2025 for semaglutide.

Which branded GLP-1 medicines do your clinicians prescribe?

When a GLP-1 is indicated, our clinicians prescribe branded, FDA-approved medicines such as Wegovy, Zepbound, Mounjaro and Ozempic. The Wegovy pill and Foundayo are options too. The choice depends on your labs, your history and your coverage.

Can I keep taking compounded GLP-1 while I join?

Tell us what you take when you join. Your clinician reviews your baseline panel and current dose with you and decides the next step together, prescribing branded medication only.

Related Reading

References

  1. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss, current as of October 1, 2026. fda.gov
  2. U.S. Food and Drug Administration. Import Alert 66-80, published October 9, 2026. fda.gov
  3. U.S. Food and Drug Administration. Medications containing semaglutide and tirzepatide marketed for type 2 diabetes or weight loss. fda.gov
  4. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine, 2021. pubmed
  5. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine, 2022. pubmed
  6. Novo Nordisk. Wegovy self-pay offer, NovoCare Pharmacy, as of November 2026. novocare.com
  7. Eli Lilly and Company. FDA approves Lilly's Foundayo (orforglipron), April 1, 2026. lilly.com
  8. Eli Lilly researchers. Preprint on an impurity in compounded tirzepatide-B12 products, March 2026. medrxiv.org